Articles

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

Princess Margaret Cancer Centre, University of Toronto, ON, Canada
Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Phoenix, AZ, USA
Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA
Division of Hematology/Oncology, Mayo Clinic Jacksonville, FL, USA
Division of Hematology, Jewish General Hospital, Montreal, QC, Canada
Gilead Sciences, Inc., Foster City, CA, USA
Gilead Sciences, Inc., Foster City, CA, USA
Gilead Sciences, Inc., Foster City, CA, USA
Gilead Sciences, Inc., Foster City, CA, USA
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Vol. 102 No. 1 (2017): January, 2017 https://doi.org/10.3324/haematol.2016.148924